Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation

We have read with great interest the paper by Trifilio and colleagues,1 entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.” The authors illustrated the result of a retrospective comparative clinical trial of an olanzapine-cont aining regimen versus an aprepitant- or fosaprepitant-containing regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan (HDMel).

Source: Clinical Lymphoma, Myeloma and Leukemia - December 22, 2017 Category: Hematology Authors: Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese, Rome Transplant Network Tags: Letter to the Editor Source Type: research